Business Context and Reporting Period
Company: DiaMedica Therapeutics Inc. (DMAC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: DiaMedica is a clinical-stage biopharmaceutical company focused on developing DM199, a recombinant KLK1 protein, for the treatment of acute ischemic stroke (AIS) and preeclampsia (PE). The company has no commercial product revenue and relies on equity financing and interest income.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(6,274) | $(4,471) | $(16,544) | $(14,220) |
| Operating Loss | $(6,883) | $(5,157) | $(18,262) | $(15,419) |
| Other Income, Net | $616 | $693 | $1,739 | $1,220 |
| Cash & Cash Equivalents | $4,134 (as of Sept 30, 2024) Marketable Securities: $46,063 Total Liquid Assets: $50,197 |
|||
| Working Capital | ||||
| Accumulated Deficit | $(132,102) |
Debt & Liquidity: The company has no long-term debt obligations other than minimal finance and operating lease liabilities ($263k total non-current liabilities). As of September 30, 2024, the company held $50.2 million in cash, cash equivalents, and marketable securities, with working capital of $46.5 million.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the nine months ended September 30, 2024, increased to $16.5 million from $14.2 million in the prior year period. This was driven primarily by higher Research and Development (R&D) expenses.
- R&D Expense Growth: R&D expenses rose to $12.6 million for the nine months ended September 30, 2024, compared to $9.4 million in 2023. This increase is attributed to the continuation of the ReMEDy2 clinical trial, expansion of the clinical team, and increased manufacturing development activity.
- G&A Expense Reduction: General and Administrative expenses decreased slightly to $5.7 million for the nine months ended September 30, 2024, from $6.0 million in 2023, due to reduced directors and officers liability insurance premiums and lower legal fees related to the ICON/PRA Netherlands lawsuit.
- Financing Activity: In June 2024, the company completed a private placement raising approximately $11.7 million in net proceeds. This contrasts with the $36.8 million raised in the same period in 2023.
Guidance, Outlook, and Risks
Outlook and Guidance
- Cash Runway: Management expects current cash resources ($50.2 million) to be sufficient to fund planned operations, including the ReMEDy2 trial and the Phase 2 PE trial, for at least the next 12 months from the date of issuance.
- Expense Trajectory: The company anticipates quarterly expenses will increase moderately as it globally expands the ReMEDy2 trial and advances the preeclampsia program.
- Revenue Timeline: No revenue is expected from product sales for at least three to four years, pending regulatory approval.
Key Risks and Contingencies
- Clinical Trial Delays: The ReMEDy2 trial for AIS continues to face slower-than-expected site activations and enrollment due to staffing shortages, protocol complexity, and competition for subjects. The company is mitigating this by expanding its internal clinical team and globalizing the trial (Canada, Australia, Georgia).
- Preeclampsia Trial Risks: The new Phase 2 investigator-sponsored study for PE (initiated Q4 2024 in South Africa) carries risks regarding timing, cost, and control, as it is not directly managed by DiaMedica personnel. Adverse results could impact the ongoing ReMEDy2 trial.
- Legal Proceedings: The company is appealing a February 2024 judgment from the Netherlands Commercial Court regarding a dispute with ICON/PRA Netherlands over clinical study data. While the court affirmed ownership of the data, it found an insufficient causal link for damages. A consolidated appeal hearing is scheduled for March 2025.
- Capital Requirements: The company will require substantial additional capital to complete development. There is no assurance that future financing will be available on favorable terms or at all.
Investor Verification Checklist
- Cash Burn Rate: Verify the monthly cash burn rate against the $50.2 million liquidity position to confirm the 12-month runway estimate.
- ReMEDy2 Enrollment: Monitor upcoming updates on site activation rates and patient enrollment numbers for the ReMEDy2 trial to assess the impact of mitigation strategies.
- PE Trial Initiation: Confirm the enrollment of the first subject in the South African preeclampsia trial and the timeline for Part 1A topline data (expected H1 2025).
- Legal Appeal Status: Track the outcome of the consolidated appeal hearing with ICON/PRA Netherlands scheduled for March 2025 regarding potential damages.
- Future Financing Needs: Assess market conditions for biotech equity financing, as the company will likely need to raise additional capital before the 12-month horizon if trial costs escalate or enrollment delays persist.